Home › Germ Cell and Embryonal Cancer › Illinois › Chicago
Germ Cell and Embryonal Cancer clinical trials in Chicago, IL
4 studies for Germ Cell and Embryonal Cancer are looking for participants at sites in and around Chicago (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
RecruitingPhase 3
- Ann and Robert H Lurie Children's Hospital of Chicago, Chicago
- University of Illinois, Chicago
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
RecruitingPhase 3
- Lurie Children's Hospital-Chicago, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
RecruitingPhase 1
- University of Chicago Medical Center, Chicago
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
RecruitingPhase 1/2
- University of Chicago, Chicago
Germ Cell and Embryonal Cancer trials in other cities
- Houston, TX6 studies
- Columbus, OH5 studies
- New York City, NY5 studies
- St. Louis, MO4 studies
- Indianapolis, IN4 studies
- Dallas, TX3 studies
- Boston, MA3 studies
- Memphis, TN3 studies
- Winston-Salem, NC3 studies
- Greenburgh, NY3 studies
- San Francisco, CA3 studies
- Clifton, NJ3 studies
Other studies in Chicago
- Non-Small Cell Lung Cancer61 studies
- Breast Cancer59 studies
- Cancer (all types)51 studies
- Metastatic Cancer45 studies
- Prostate Cancer45 studies
- Lung Cancer41 studies
- Obesity41 studies
- Ovarian Cancer36 studies
- Colorectal Cancer34 studies
- Stroke34 studies
- Heart Failure31 studies
- Overweight29 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.